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Summary of international opinions on power morcellation.
Key points to consider
1. Consent should include the following information:
a. Beneﬁts of laparoscopy vs. laparotomy
b. Detailed risks of morcellation
c. Incidence of unexpected sarcomaz 1:350e1:1000
d. No reliable preoperative investigations
e. Prognosis may worsen if unsuspected cancer is morcellated
2. Morcellation is contraindicated if malignancy is suspected or if known
malignancy
3. Morcellation is relatively contraindicated in the perimenopausal and
postmenopausal womenBackground
The USA Food and Drug Administration (FDA) ﬁrst approved the
use of laparoscopic power morcellators for gynecologic surgery in
1995. Theuseof powermorcellators enables surgeons to extract large
uteri and/orﬁbroidswhilst retaining thebeneﬁts of laparoscopic sur-
gery. The risks associatedwithusingapowermorcellator canbe cate-
gorized into direct and indirect injuries. Direct injuries involve
trauma to vessels, nerves, and visceral organs. Indirect injuries
include: (1) dissemination of benign disease such as endometriosis
and leiomyomas; (2) dissemination of unsuspected malignancy;
and (3) delayed or missing diagnosis of cancer. The rate of reported
morcellator-related injuries is low: between 1% and 2%.1,2
In 2013, a campaignwas launched against the use of powermor-
cellators following a case of dissemination of unsuspected leiomyo-
sarcoma (LMS) after elective laparoscopic hysterectomy for
presumed ﬁbroids. This has led to a cascade of events worldwide
affecting patients, clinicians, and industry.
The US FDA issued the ﬁrst warning in April 2014 citing the risk
of LMS to be as high as 1 in 350. Given that there is no reliable way
of distinguishing between a benign ﬁbroid and LMS, the FDA
banned the use of power morcellators for laparoscopic myomec-
tomy and hysterectomy. This guidance faced huge criticism, as
the data analyzed was small and heterogeneous. Subsequently,
the guidance was revised. Worldwide, international health organi-
zations such as the AAGL, ACOG, APAGE, SCOG, and ESGE have is-
sued statements regarding the use of power morcellators. Their
recommendations are summarized in Table 1.
Our response
In light of these concerns and the paucity of robust evidence,
how should we, as clinicians, respond? There are simply two
main options the clinician could consider: (1) stopping power mor-
cellation altogether; and (2) continue with this technique. Clini-
cians will need to balance the risk of open abdominal surgery
versus the risk of disseminating unsuspected cancer.
Stop power morcellation
These events have caused clinicians worldwide to change their
practice and stop the use of power morcellation. Since 2013, there
was a notable decrease in laparoscopic hysterectomies (9%) and
myomectomies (17%) performed in our unit.Conﬂicts of interest: No conﬂicts of interest.
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and counselling for open hysterectomy? The answer is likely to
be no.In light of concerns with power morcellation, how should






Good Level 1 evidence proves that clinicians are exposing pa-
tients to higher risks of procedure-related complications such as
thromboembolism, increase blood loss, blood transfusions, hernias,
and infections.3,4
In addition, Siedhoff et al5 published a decision tree analysis,
which predicted that there were more overall hysterectomy-
related-deaths with open versus laparoscopic hysterectomy (103
vs. 98 per 100,000). This article assumed a hypothetical cohort of
100,000 premenopausal women who underwent hysterectomy
for ﬁbroids. There were more LMS-related deaths in laparoscopic
hysterectomies (86 vs. 71 per 100,000) and conversely there were
more procedure-related deaths in open hysterectomies (32 vs. 12
per 100,000).
Effectively, clinicians choosing the open approach will be sub-
jecting patients to increase surgical morbidity with possibly higher
or no difference in mortality rates.4. No reliable preoperative diagnosis
5. Discuss alternative treatment options
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Figure 2. Tissue fragments remain within the bag after morcellation allowing ease of
tissue removal and dissemination of tissue.
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Assuming the above, efforts should be made to continue and not
abandon power morcellation. Clinicians can choose to continue
open morcellation in all cases or perform selective morcellation,
both with informed consent.
All cases
The true incidence of unexpected LMS has yet to be determined.
Published studies report the incidence to range from 1:350 to
1:1000. In our unit, our 10 years of retrospective data suggest
that the incidence was found to be approximately 1:1000. There
were three cases of unexpected sarcoma encountered in 3013 cases
of laparoscopic myomectomies performed for presumed ﬁbroids.6
The incidence of sarcoma increases with age, steadily rising from
the 4th decade and peaking in the 7th decade.
Evidence is also lacking on whether power morcellation itself
worsens prognosis. The frequently cited studies evaluating the
impact of morcellation on prognosis included both manual and po-
wer morcellation. However, presently, it would be prudent to
accept that morcellation alone, with or without power, spreads
cancerous tissue and may increase recurrence and decrease overall
survival rates.7
Selected cases
There are no deﬁnitive preoperative investigations that are able
to differentiate between a benign ﬁbroid and LMS. Radiologic imag-
ing (ultrasound, magnetic resonance, computed tomography),
biochemical markers (Ca-125, lactate dehydrogenase), histological
(endometrial sampling and needle biopsy) all have poor sensitivity
and speciﬁcity for LMS. Targeted molecular imaging with the
16-alpha-[18F]-ﬂuoroestradiol (FES)molecule shows some promise
but more studies are required. Notably, a small study published by
Goto et al concluded a 100% sensitivity and speciﬁcity with dy-
namic magnetic resonance imaging and serum lactate dehydroge-
nase measurement.8
The current guidelines on power morcellation surmise that, by
triaging patients into high and low risk categories, clinicians may
safely morcellate. However, there will be patients classiﬁed as
low risk who will have unexpected sarcoma. The majority of pa-
tients who are classiﬁed as high risk will have benign disease due
to the rarity of LMS.
Future: contained morcellation
Contained morcellation intends to improve the safety proﬁle of
power morcellation by reducing the risk of dissemination. TheFigure 1. Contained morcellation within a pseudopneumoperitoneum keeping sur-
rounding organs away from the operating ﬁeld.concept behind contained morcellation is not new. Clinicians
have been modifying existing tissue retrieval bags in which to
perform morcellation. This is to avoid spillage or spread of
tissue within the abdominal cavity. The additional beneﬁt of using
a contained system aids the ease of removal of tissue fragments af-
ter morcellation. It also creates a safe operating ﬁeld by keeping the
bowels away from the morcellator (Figures 1 and 2).
There are now various bags on the market speciﬁcally designed
for use with power morcellators. The More-Cell-Safe system and
MorSafe bag has achieved the CE certiﬁcation and more recently
the PneumoLiner gained US FDA approval. The choice of bag is
based on surgeon preference but should take into account the
following:
1) The material used to make the bag has been shown to be
impermeable to tissue and liquids at sufﬁcient pressure.
2) The material should be clear or translucent to allow visualiza-
tion of surrounding organs.
3) The bag is large enough to accommodate the specimen and
allow for adequate insufﬂation to obtain a good operating ﬁeld
or pseudopneumoperitoneum; i.e., distance between morcella-
tor and surrounding organs.
4) The design of the bag allows for the laparoscope to be inserted
to let morcellation to be performed under direct vision.
5) The bag is easy to use to limit additional operating time.
6) The bag is of minimal additional cost to the patient.Conclusion
Contained morcellation allows the surgeon to safely continue
intra-abdominal manual or power morcellation without the abso-
lute need for triage. It should not be undertaken in cases with
known or suspected malignancy. Arguably, there is no robust evi-
dence to support contained morcellation, although logical sense
dictates that it will probably minimize the risk of dissemination
of both benign and malignant tissue. Long-term multicenter pro-
spective data should be collected to evaluate its use.References
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